2012
Practice patterns in the use of adjuvant therapy for post-menopausal early-stage breast cancer in the pre- and post-Onco type DX era.
Latif A, Small A, Moshier E, Adelson K, Raptis G, Godbold J, Oh W, Galsky M. Practice patterns in the use of adjuvant therapy for post-menopausal early-stage breast cancer in the pre- and post-Onco type DX era. Journal Of Clinical Oncology 2012, 30: e21032-e21032. DOI: 10.1200/jco.2012.30.15_suppl.e21032.Peer-Reviewed Original ResearchAdjuvant therapyOncotype DXHormonal therapyPatient ageStage IPractice patternsEarly-stage breast cancerAdjuvant hormonal therapyNational Cancer DatabaseProportion of patientsUse of chemotherapyBreast cancer patientsLog-binomial regressionBr-CANode negativePrevalence ratiosToxic therapiesCancer patientsPredictive biomarkersCancer DatabaseTreatment utilizationBreast cancerChemotherapyPatientsTherapy
2005
Treatment of hot flushes in breast and prostate cancer
Adelson KB, Loprinzi CL, Hershman DL. Treatment of hot flushes in breast and prostate cancer. Expert Opinion On Pharmacotherapy 2005, 6: 1095-1106. PMID: 15957964, DOI: 10.1517/14656566.6.7.1095.Peer-Reviewed Original ResearchMeSH KeywordsAminesAntineoplastic Agents, HormonalBreast NeoplasmsCimicifugaContraindicationsCyclohexanecarboxylic AcidsDrug Therapy, CombinationElectroacupunctureExcitatory Amino Acid AntagonistsFemaleGabapentinGamma-Aminobutyric AcidHormone Replacement TherapyHot FlashesHumansMaleNeoplasms, Hormone-DependentOrchiectomyParoxetinePhytotherapyPlant PreparationsProstatic NeoplasmsRandomized Controlled Trials as TopicSelective Serotonin Reuptake InhibitorsConceptsHormone replacement therapyHot flushesBreast cancerReplacement therapyProstate cancerSelective serotonin reuptake inhibitorsChemotherapy-induced menopauseMenopausal age womenMainstay of treatmentThrombo-embolic eventsSerotonin reuptake inhibitorsHealthy menopausal womenCommon health problemHot flush symptomsQuality of lifeMedical castrationHormonal therapyOvarian suppressionAndrogen ablationPerimenopausal periodNonhormonal agentsReuptake inhibitorsSignificant morbidityCancer survivorsMenopausal women